These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 39018723)

  • 1. Clinical Outcomes and Risk Stratification in Patients With Metastatic Hormone-Sensitive Prostate Cancer Treated With New-Generation Androgen Receptor Signaling Inhibitors.
    Suzuki K; Shiraishi Y; Furukawa J; Okamura Y; Bando Y; Hara T; Okada K; Terakawa T; Hyodo Y; Chiba K; Teishima J; Nakano Y; Miyake H
    Clin Genitourin Cancer; 2024 Oct; 22(5):102140. PubMed ID: 39018723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of multiple androgen receptor signaling inhibitor medicines with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a study in the real world.
    Lu Y; Jiang J; Yang G; Ding H; Zheng Q; Ji L; Wang Y; Dong Z; Zhai Z; Tian J; Zhang Y; Wang J; Yang L; Wang Z
    Front Oncol; 2024; 14():1324181. PubMed ID: 38699643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen Receptor Signaling Inhibitors in Addition to Docetaxel with Androgen Deprivation Therapy for Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis.
    Yanagisawa T; Rajwa P; Thibault C; Gandaglia G; Mori K; Kawada T; Fukuokaya W; Shim SR; Mostafaei H; Motlagh RS; Quhal F; Laukhtina E; Pallauf M; Pradere B; Kimura T; Egawa S; Shariat SF
    Eur Urol; 2022 Dec; 82(6):584-598. PubMed ID: 35995644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative efficacy of second-generation androgen receptor inhibitors for treating prostate cancer: A systematic review and network meta-analysis.
    Chen X; Wang Q; Pan Y; Wang S; Li Y; Zhang H; Xu M; Zhou H; Liu X
    Front Endocrinol (Lausanne); 2023; 14():1134719. PubMed ID: 36967752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact.
    Gasperoni L; Giunta EF; Montanari D; Masini C; De Giorgi U
    Expert Opin Drug Metab Toxicol; 2024 Jun; 20(6):491-502. PubMed ID: 38778707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis.
    Wenzel M; Würnschimmel C; Nocera L; Collà Ruvolo C; Tian Z; Shariat SF; Saad F; Briganti A; Tilki D; Graefen M; Kluth LA; Roos FC; Mandel P; Chun FKH; Karakiewicz PI
    Eur Urol Focus; 2022 Mar; 8(2):399-408. PubMed ID: 33853754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors in Hormone-sensitive Prostate Cancer Patients Treated With Combined Androgen Blockade: A Consecutive 15-year Study at a Single Japanese Institute.
    Miyazawa Y; Sekine Y; Arai S; Oka D; Nakayama H; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Suzuki K
    In Vivo; 2021; 35(1):373-384. PubMed ID: 33402486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-world prostate-specific antigen reduction and survival outcomes of metastatic hormone-sensitive prostate cancer patients treated with apalutamide: An observational, retrospective, and multicentre study.
    López-Abad A; Ramírez Backhaus M; Server Gómez G; Cao Avellaneda E; Moreno Alarcón C; López Cubillana P; Yago Giménez P; de Pablos Rodríguez P; Juan Fita MJ; Climent Durán MÁ; Guardiola Ruiz I; Vidal Crespo N; Artés Artés M; Montoya Chinchilla R; Moreno Avilés J; Guzmán Martínez-Valls PL; López González PÁ
    Prostate Int; 2024 Mar; 12(1):20-26. PubMed ID: 38523897
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life in patients with metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors: the role of combination treatment therapy.
    Afferi L; Longoni M; Moschini M; Gandaglia G; Morgans AK; Cathomas R; Mattei A; Breda A; Scarpa RM; Papalia R; de Nunzio C; Esperto F
    Prostate Cancer Prostatic Dis; 2024 Jun; 27(2):173-182. PubMed ID: 37055663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of disease volume on survival efficacy of triplet therapy for metastatic hormone-sensitive prostate cancer: a systematic review, meta-analysis, and network meta-analysis.
    Matsukawa A; Rajwa P; Kawada T; Bekku K; Laukhtina E; Klemm J; Pradere B; Mori K; Karakiewicz PI; Kimura T; Chlosta P; Shariat SF; Yanagisawa T
    Int J Clin Oncol; 2024 Jun; 29(6):716-725. PubMed ID: 38582807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of the pretreatment lung immune prognostic index in patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhao J; Chen J; Zhu S; Dai J; Ni Y; Xu N; Zhao F; He B; Zhang X; Liang J; Sun G; Liu Z; Shen P; Zeng H
    Ann Transl Med; 2023 Mar; 11(5):201. PubMed ID: 37007568
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol.
    Attard G; Murphy L; Clarke NW; Cross W; Jones RJ; Parker CC; Gillessen S; Cook A; Brawley C; Amos CL; Atako N; Pugh C; Buckner M; Chowdhury S; Malik Z; Russell JM; Gilson C; Rush H; Bowen J; Lydon A; Pedley I; O'Sullivan JM; Birtle A; Gale J; Srihari N; Thomas C; Tanguay J; Wagstaff J; Das P; Gray E; Alzoueb M; Parikh O; Robinson A; Syndikus I; Wylie J; Zarkar A; Thalmann G; de Bono JS; Dearnaley DP; Mason MD; Gilbert D; Langley RE; Millman R; Matheson D; Sydes MR; Brown LC; Parmar MKB; James ND;
    Lancet; 2022 Jan; 399(10323):447-460. PubMed ID: 34953525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic therapies for metastatic hormone-sensitive prostate cancer: network meta-analysis.
    Mori K; Mostafaei H; Sari Motlagh R; Pradere B; Quhal F; Laukhtina E; Schuettfort VM; Kramer G; Abufaraj M; Karakiewicz PI; Kimura T; Egawa S; Shariat SF
    BJU Int; 2022 Apr; 129(4):423-433. PubMed ID: 34171173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trends in the Use of Second-Generation Androgen Receptor Axis Inhibitors for Metastatic Hormone-Sensitive Prostate Cancer and Clinical Factors Predicting Biological Recurrence.
    Nakane K; Watanabe H; Naiki T; Takahara K; Yasui T; Miyake H; Shiroki R; Koie T
    Diagnostics (Basel); 2023 May; 13(9):. PubMed ID: 37175052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of intraductal carcinoma of the prostate in treatment selection for metastatic hormone-sensitive prostate cancer.
    Naito Y; Kato M; Kawanishi H; Yamamoto A; Sakamoto F; Hirabayashi H; Kobayashi M; Matsukawa Y; Kimura T; Araki H; Nishikimi T; Kondo A; Yoshino Y; Hashimoto Y; Nakano Y; Tsuzuki T
    Prostate; 2023 Mar; 83(4):307-315. PubMed ID: 36420892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natural course of metastatic castration-resistant prostate cancer in the era of intensified androgen deprivation therapy in the hormone-sensitive setting.
    Gebrael G; Hage Chehade C; Sayegh N; Tripathi N; Chigarira B; Goel D; Nordblad B; McFarland TR; Narang A; Srivastava A; Tandar C; Dal E; Jo Y; Galarza Fortuna G; Mathew Thomas V; Sahu KK; Li H; Maughan BL; Swami U; Agarwal N
    Prostate; 2024 Jun; 84(9):888-892. PubMed ID: 38561317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in the treatment landscape of metastatic hormone-sensitive prostate cancer following approval of upfront androgen receptor signaling inhibitors: A multicenter study.
    Urabe F; Muramoto K; Yanagisawa T; Fukuokaya W; Mori K; Tashiro K; Katsumi K; Takahashi H; Yoshihara K; Miyajima K; Imai Y; Iwatani K; Kayano S; Igarashi T; Murakami M; Tsuzuki S; Shimomura T; Yamada H; Miki J; Kimura T;
    Int J Urol; 2024 Jul; ():. PubMed ID: 39031448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes of Patients with High-risk Metastatic Hormone-naïve Prostate Cancer: A 3-year Interim Analysis of the Observational J-ROCK Study.
    Miyake H; Matsumoto R; Fujimoto K; Mizokami A; Uemura H; Kamoto T; Kawakami S; Nakamura K; Maekawa S; Shibayama K; Watanabe A; Ito M; Tajima Y; Matsuyama H; Uemura H
    Eur Urol Oncol; 2024 Jun; 7(3):625-632. PubMed ID: 38296736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive factors for the efficacy of abiraterone acetate therapy in high-risk metastatic hormone-sensitive prostate cancer patients.
    Ueda T; Fujita K; Nishimoto M; Shiraishi T; Miyashita M; Kayukawa N; Nakamura Y; Sako S; Ogura R; Fujihara A; Minami T; Hongo F; Okihara K; Yoshimura K; Uemura H; Ukimura O
    World J Urol; 2022 Dec; 40(12):2939-2946. PubMed ID: 36331614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Whole blood
    Kwan EM; Fettke H; Crumbaker M; Docanto MM; To SQ; Bukczynska P; Mant A; Ng N; Foroughi S; Graham LK; Haynes AM; Azer S; Lim LE; Segelov E; Mahon K; Davis ID; Parente P; Pezaro C; Todenhöfer T; Sathianathen N; Hauser C; Horvath LG; Joshua AM; Azad AA
    Transl Androl Urol; 2021 Apr; 10(4):1688-1699. PubMed ID: 33968657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.